Viela Bio (Viela Bio) Change In Inventory : $0.00 Mil (TTM As of Dec. 2020)

View and export this data going back to 2019. Start your Free Trial

What is Viela Bio Change In Inventory?

Viela Bio's change in inventory for the quarter that ended in Dec. 2020 was $0.00 Mil. It means Viela Bio's inventory stayed the same from Sep. 2020 to Dec. 2020 .

Viela Bio's change in inventory for the fiscal year that ended in Dec. 2020 was $0.00 Mil. It means Viela Bio's inventory stayed the same from Dec. 2019 to Dec. 2020 .

Viela Bio's Total Inventories for the quarter that ended in Dec. 2020 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Viela Bio's Days Inventory for the quarter that ended in Dec. 2020 was 14.38.

Inventory Turnover measures how fast the company turns over its inventory within a year. Viela Bio's Inventory Turnover for the quarter that ended in Dec. 2020 was 6.35.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Viela Bio's Inventory-to-Revenue for the quarter that ended in Dec. 2020 was 0.02.

Viela Bio Change In Inventory Historical Data

The historical data trend for Viela Bio's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viela Bio Change In Inventory Chart

Viela Bio Annual Data

Trend

Dec18

Dec19

Dec20

Change In Inventory

Viela Bio Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Change In Inventory	Get a 7-Day Free Trial					-	-	-	-	-

Viela Bio Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Viela Bio (NAS:VIE) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Viela Bio's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0.219	/	1.39	*	365 / 4
	=	14.38

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Viela Bio's Inventory Turnover for the quarter that ended in Dec. 2020 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	1.39	/	0.219
	=	6.35

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Viela Bio's Inventory to Revenue for the quarter that ended in Dec. 2020 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0.219	/	9.336
	=	0.02

Viela Bio Change In Inventory Related Terms

Thank you for viewing the detailed overview of Viela Bio's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Viela Bio (Viela Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viela Bio Inc (NAS:VIE) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

One MedImmune Way, First Floor, Area Two, Gaithersburg, MD, USA, 20878

Website

https://www.vielabio.com

Viela Bio Inc is a clinical-stage biotechnology company engaged in developing and commercializing transformative treatments for severe inflammation and autoimmune diseases. Its product inebilizumab, is a humanized monoclonal antibody, designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells.

Executives

Chris Nolet	director	C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Rachelle Suzanne Jacques	director	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Edward Hu	director	10975 TORREY PINES ROAD, LA JOLLA CA 92037
Boyu Capital General Partner Iii, L.p.	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital General Partner Iii, Ltd.	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Group Holdings Ltd.	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Xyxy Holdings Ltd.	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Investment Management Ltd	10 percent owner	SUITE 1501, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boundless Meadow Ltd	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Xiaomeng Tong	director, 10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Yanling Cao	director, 10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Fund Iii, L.p.	10 percent owner	C/O MAPLES CORPORATE SERVICES LIMITED BOX 309, UGLAND HOUSE GRAND CAYMAN E9 KYL-1104
Boyu Capital Opportunities Master Fund	10 percent owner	CAYMAN CORPORATE CENTRE 27 HOSPITAL ROAD, GEORGE TOWN CAYMAN ISLANDS E9 KY1-9008
Zhengbin Yao	director, officer: Chief Executive Officer	10301 STELLA LINK ROAD, HOUSTON TX 77025
William Ragatz	officer: VP, Head of Commercial	C/O VIELA BIO, INC., ONE MEDIMMUNE WAY FIRST FLOOR, AREA TWO GAITHERSBURG MD 20878